Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022. 

X4 Pharmaceuticals

Zogenix

Personalis

GenSight Biologics

Alnylam Pharmaceuticals

Amarin

Phathom Pharmaceuticals

Avedro

Jasper Therapeutics

CRISPR Therapeutics

Dicerna Pharmaceuticals

Senseonics

Effector Therapeutics

Sientra

Spruce Biosciences

Vaxcyte

Vera Therapeutics

Verona Pharma

Abingworth

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

Google Maps

Global Site Tag

Principal

Jacqueline Grant

Jay Cui

Partner

Jayson Punwani

Managing Director and Executive Partner

Tim Haines

Executive Assistant/Office Manager

Elizabeth O'Brien

Operations Manager, US

Gwen Kinard

Senior Finance Manager

Katie Stirrup

Executive Assistant / Office Manager

Sofia Jara

Andrew Sinclair

Partner, Portfolio Manager

Peter Goodfellow

John Shields

Chairman and Managing Partner

Kurt von Emster

Managing Partner

James Abell

Partner and CFO

Alex Asquith

General Counsel and Chief Financial Officer

David Leathers

Special Partner

Shelley Chu

Vincent Miles

Partner & Portfolio Manager

Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.

Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Gynesonics develops transcervical, uterus-preserving, incision-less technologies for diagnostic and therapeutic applications.

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. 

London Early Stage Venture Investors

Venture Stage Investors with Investments in Africa

Private Equity Stage Investors with Investments in London, England

Venture Stage Investors with Investments in West Coast

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors.

Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

Abingworth Clinical Co-Development Co-Investment Fund

Abingworth Clinical Co-Development Fund 2

Abingworth Bioventures VIII

Abingworth Bioventures VII

Abingworth Clinical Co-Development Fund LP

Abingworth Bioventures VI LP

Abingworth Bioventures IV LP

Advertising, Business and Retail Services

London

England

United Kingdom

Europe

European VC Funding Drops To Lowest Quarter In 4 Years, Despite Uptick For German Startups

Abingworth appoints Robert DeBenedetto as Managing Director – Clinical Co-Development

Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler

Tech transfer office body appoints Abingworth MD as chair

United States

North America

Indonesia

Asia

India

Bangladesh

Pakistan

HTML5

jQuery

Symantec Email Security.Cloud

F5 NGINX

Microsoft Outlook

Vimeo

Google Fonts

Office 365

Adobe Fonts

Apache Server

Venture capital firm investing in technology and healthcare sectors

Sequoia Capital

Venture capital firm specializing in investing in software and internet startups

Andreessen Horowitz

Global healthcare investment firm specializing in biopharmaceutical and medical device companies

OrbiMed Advisors

Abingworth LLP (formerly Abingworth Management Ltd.) is a transatlantic bioscience investment firm that has been investing in life science and healthcare services companies since the early days of the biotechnology industry. The company has helped young biopharma companies on both sides of the Atlantic turn scientific discoveries into new treatments for patients.

Abingworth LLP

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 21, 2024 3:36 PM	ceb5e49e
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 21, 2024 3:36 PM	2be1c4e0
company summary	general
signals	general	Feb 21, 2024 3:36 PM	068db905
crunchbase trigger	general	Nov 25, 2024 9:06 AM	adbaad6e
crunchbase profile	general	Nov 25, 2024 11:34 AM	5bffd26e
li profile	general	Feb 21, 2024 3:36 PM	9699c97c
translate crunchbase fundingrounds	general	Nov 25, 2024 2:15 PM	25927937
peers	general	Feb 21, 2024 3:36 PM	0b615230
news basic	general	Feb 21, 2024 3:36 PM	7a9e4a3a
bundesanzeiger	filings	Feb 21, 2024 3:36 PM	13c001cf
financials download nd	financials
private financials	financials

COM:ABINGWORTH

Abingworth LLP